Skip to main content
Top
Published in: Surgical Endoscopy 1/2015

Open Access 01-01-2015 | New Technology

Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial

Authors: Johannes Zacherl, Aviel Roy-Shapira, Luigi Bonavina, Amol Bapaye, Ralf Kiesslich, Sebastian F. Schoppmann, William R. Kessler, Don J. Selzer, Ryan C. Broderick, Glen A. Lehman, Santiago Horgan

Published in: Surgical Endoscopy | Issue 1/2015

Login to get access

Abstract

Background

Both long-term proton pump inhibitor (PPI) use and surgical fundoplication have potential drawbacks as treatments for chronic gastroesophageal reflux disease (GERD). This multi-center, prospective study evaluated the clinical experiences of 69 patients who received an alternative treatment: endoscopic anterior fundoplication with a video- and ultrasound-guided transoral surgical stapler.

Methods

Patients with well-categorized GERD were enrolled at six international sites. Efficacy data was compared at baseline and at 6 months post-procedure. The primary endpoint was a ≥50 % improvement in GERD health-related quality of life (HRQL) score. Secondary endpoints were elimination or ≥50 % reduction in dose of PPI medication and reduction of total acid exposure on esophageal pH probe monitoring. A safety evaluation was performed at time 0 and weeks 1, 4, 12, and 6 months.

Results

66 patients completed follow-up. Six months after the procedure, the GERD-HRQL score improved by >50 % off PPI in 73 % (48/66) of patients (95 % CI 60–83 %). Forty-two patients (64.6 %) were no longer using daily PPI medication. Of the 23 patients who continued to take PPI following the procedure, 13 (56.5 %) reported a ≥50 % reduction in dose. The mean percent of total time with esophageal pH <4.0 decreased from baseline to 6 months (P < 0.001). Common adverse events were peri-operative chest discomfort and sore throat. Two severe adverse events requiring intervention occurred in the first 24 subjects, no further esophageal injury or leaks were reported in the remaining 48 enrolled subjects.

Conclusions

The initial 6-month data reported in this study demonstrate safety and efficacy of this endoscopic plication device. Early experience with the device necessitated procedure and device changes to improve safety, with improved results in the later portion of the study. Continued assessment of durability and safety are ongoing in a three-year follow-up study of this patient group.
Literature
1.
go back to reference Dent J, Holloway RH, Toouli J, Dodds WJ (1988) Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 29:1020–1028PubMedCentralPubMedCrossRef Dent J, Holloway RH, Toouli J, Dodds WJ (1988) Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 29:1020–1028PubMedCentralPubMedCrossRef
2.
go back to reference Tack J, Becher A, Mulligan C, Johnson DA (2012) Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther 35:1257–1266PubMedCrossRef Tack J, Becher A, Mulligan C, Johnson DA (2012) Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther 35:1257–1266PubMedCrossRef
3.
go back to reference Fass R (2007) Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 67:1521–1530PubMedCrossRef Fass R (2007) Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 67:1521–1530PubMedCrossRef
4.
go back to reference Lu M, Malladi V, Agha A, Abydayyeh S, Han C, Siepman N, Graham DY (2007) Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. Dig Dis Sci 2052:2813–2820CrossRef Lu M, Malladi V, Agha A, Abydayyeh S, Han C, Siepman N, Graham DY (2007) Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. Dig Dis Sci 2052:2813–2820CrossRef
5.
go back to reference Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO (2012) Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. Dis Esophagus 25:682–686PubMedCrossRef Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO (2012) Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. Dis Esophagus 25:682–686PubMedCrossRef
6.
go back to reference Milkes D, Gerson LB, Triadafilopoulos G (2004) Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 99:991–996PubMedCrossRef Milkes D, Gerson LB, Triadafilopoulos G (2004) Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 99:991–996PubMedCrossRef
7.
go back to reference Crawley JA, Schmitt CM (2000) How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. Clin Outcomes Manag 7:29–34 Crawley JA, Schmitt CM (2000) How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. Clin Outcomes Manag 7:29–34
8.
go back to reference Gallup Organization (2000) The 2000 gallup study of consumers’ use of stomach relief products. Gallup Organization, Princeton Gallup Organization (2000) The 2000 gallup study of consumers’ use of stomach relief products. Gallup Organization, Princeton
9.
go back to reference Kahrilas PJ, Howden CW, Hughes N (2011) Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 106:1419–1425PubMedCrossRef Kahrilas PJ, Howden CW, Hughes N (2011) Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 106:1419–1425PubMedCrossRef
10.
go back to reference Vakil NB, Traxler B, Levine D (2004) Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2:665–668PubMedCrossRef Vakil NB, Traxler B, Levine D (2004) Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2:665–668PubMedCrossRef
11.
go back to reference Chey WD, Mody RR, Wu EQ et al (2009) Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 25:1869–1878PubMedCrossRef Chey WD, Mody RR, Wu EQ et al (2009) Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 25:1869–1878PubMedCrossRef
12.
go back to reference Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO (2006) Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 55:1398–1402PubMedCentralPubMedCrossRef Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO (2006) Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 55:1398–1402PubMedCentralPubMedCrossRef
13.
go back to reference Bytzer P, Zanten SV, Mattsson H, Wernersson B (2012) Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis: a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 36:635–643PubMedCrossRef Bytzer P, Zanten SV, Mattsson H, Wernersson B (2012) Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis: a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 36:635–643PubMedCrossRef
14.
go back to reference Johnson DA, Oldfield EC 4th (2013) Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol 11:458–464PubMedCrossRef Johnson DA, Oldfield EC 4th (2013) Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol 11:458–464PubMedCrossRef
15.
go back to reference Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519–526PubMedCentralPubMedCrossRef Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519–526PubMedCentralPubMedCrossRef
16.
go back to reference Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310:2435–2442PubMedCrossRef Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310:2435–2442PubMedCrossRef
17.
go back to reference Kellokumpu L, Voutilainen M, Haglund C, Färkkilä M, Roberts PJ, Kautiainen H (2013) Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. World J Gastroenterol 19:2818–3810CrossRef Kellokumpu L, Voutilainen M, Haglund C, Färkkilä M, Roberts PJ, Kautiainen H (2013) Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. World J Gastroenterol 19:2818–3810CrossRef
18.
go back to reference Broeders JA, Roks DJ, Ahmed Ali U, Watson DI, Baigrie RJ, Cao Z, Hartmann J, Maddern GJ (2013) Laparoscopic anterior 180-degree versus Nissen fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis of randomized clinical trials. Ann Surg 257:850–859PubMedCrossRef Broeders JA, Roks DJ, Ahmed Ali U, Watson DI, Baigrie RJ, Cao Z, Hartmann J, Maddern GJ (2013) Laparoscopic anterior 180-degree versus Nissen fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis of randomized clinical trials. Ann Surg 257:850–859PubMedCrossRef
19.
go back to reference Klaus A, Hinder RA, DeVault KR, Achem SR (2003) Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course. Am J Med 114:6–9PubMedCrossRef Klaus A, Hinder RA, DeVault KR, Achem SR (2003) Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course. Am J Med 114:6–9PubMedCrossRef
20.
go back to reference Bowrey DJ, Blom D, Crookes PF, Bremner CG, Johansson JL, Lord RV, Peters JH (2001) Risk factors and the prevalence of trocar site herniation after laparoscopic fundoplication. Surg Endosc 15:663–666PubMedCrossRef Bowrey DJ, Blom D, Crookes PF, Bremner CG, Johansson JL, Lord RV, Peters JH (2001) Risk factors and the prevalence of trocar site herniation after laparoscopic fundoplication. Surg Endosc 15:663–666PubMedCrossRef
21.
go back to reference Kauer WK, Roy-Shapira A, Watson D, Sonnenschein M, Sonnenschein E, Unger J, Voget M, Stein HJ (2009) Preclinical trial of a modified gastroscope that performs a true anterior fundoplication for the endoluminal treatment of gastroesophageal reflux disease. Surg Endosc 23:2728–2731PubMedCrossRef Kauer WK, Roy-Shapira A, Watson D, Sonnenschein M, Sonnenschein E, Unger J, Voget M, Stein HJ (2009) Preclinical trial of a modified gastroscope that performs a true anterior fundoplication for the endoluminal treatment of gastroesophageal reflux disease. Surg Endosc 23:2728–2731PubMedCrossRef
22.
go back to reference Velanovich V (2007) The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 20:130–13423PubMedCrossRef Velanovich V (2007) The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 20:130–13423PubMedCrossRef
23.
go back to reference Hill LD, Kozarek RA, Kraemer SJ, Aye RW, Mercer CD, Low DE, Pope CE 2nd (1996) The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 44:541–547PubMedCrossRef Hill LD, Kozarek RA, Kraemer SJ, Aye RW, Mercer CD, Low DE, Pope CE 2nd (1996) The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 44:541–547PubMedCrossRef
24.
go back to reference Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, Albertucci M (1992) Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 87:1102–1111PubMed Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, Albertucci M (1992) Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 87:1102–1111PubMed
25.
go back to reference Cadiere GB, Rajan A, Germay O et al (2008) Endoluminal fundoplication by a transoral device for the treatment of GERD: a feasibility study. Surg Endosc 22:333–342PubMedCrossRef Cadiere GB, Rajan A, Germay O et al (2008) Endoluminal fundoplication by a transoral device for the treatment of GERD: a feasibility study. Surg Endosc 22:333–342PubMedCrossRef
26.
go back to reference Cadière GB, Buset M, Muls V, Rajan A, Rösch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Devière J (2008) Antireflux transoral incisionless fundoplication using esophyX: 12-month results of a prospective multicenter study. World J Surg 32:1676–1688PubMedCentralPubMedCrossRef Cadière GB, Buset M, Muls V, Rajan A, Rösch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Devière J (2008) Antireflux transoral incisionless fundoplication using esophyX: 12-month results of a prospective multicenter study. World J Surg 32:1676–1688PubMedCentralPubMedCrossRef
27.
go back to reference Locke GR 3rd, Horwhat J, Mashimo H, Savarino E, Zentilin P, Savarino V, Zerbib F, Armbruster SP, Wong RK, Moawad F (2013) Endotherapy for and tailored approaches to treating GERD, and refractory GERD. Ann N Y Acad Sci 1300:166–186PubMedCrossRef Locke GR 3rd, Horwhat J, Mashimo H, Savarino E, Zentilin P, Savarino V, Zerbib F, Armbruster SP, Wong RK, Moawad F (2013) Endotherapy for and tailored approaches to treating GERD, and refractory GERD. Ann N Y Acad Sci 1300:166–186PubMedCrossRef
28.
go back to reference Lipham JC, DeMeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, Bemelman W (2012) The LINX® reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc 26:2944–2949PubMedCrossRef Lipham JC, DeMeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, Bemelman W (2012) The LINX® reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc 26:2944–2949PubMedCrossRef
29.
go back to reference Bonavina L, Saino G, Bona D, Sironi A, Lazzari V (2013) One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. J Am Coll Surg 217:577–585PubMedCrossRef Bonavina L, Saino G, Bona D, Sironi A, Lazzari V (2013) One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. J Am Coll Surg 217:577–585PubMedCrossRef
30.
go back to reference Ganz RA, Peters JH, Horgan S, Bemelman WA, Dunst CM, Edmundowicz SA, Taiganides PA (2013) Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 368:719–727PubMedCrossRef Ganz RA, Peters JH, Horgan S, Bemelman WA, Dunst CM, Edmundowicz SA, Taiganides PA (2013) Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 368:719–727PubMedCrossRef
Metadata
Title
Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial
Authors
Johannes Zacherl
Aviel Roy-Shapira
Luigi Bonavina
Amol Bapaye
Ralf Kiesslich
Sebastian F. Schoppmann
William R. Kessler
Don J. Selzer
Ryan C. Broderick
Glen A. Lehman
Santiago Horgan
Publication date
01-01-2015
Publisher
Springer US
Published in
Surgical Endoscopy / Issue 1/2015
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-014-3731-3

Other articles of this Issue 1/2015

Surgical Endoscopy 1/2015 Go to the issue